Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award | Director | King Fahad Specialist Hospital | Saudi Arabia

Dr. Kholoud Alwosaibai is a highly accomplished biomedical scientist, cancer geneticist, and immunotherapy specialist with over fifteen years of progressive experience in translational oncology, molecular medicine, and clinical genomics. She currently serves as the Director of the Biomedical Research Department at King Fahad Specialist Hospital in Dammam, Saudi Arabia, where she leads multiple funded national research programs in cancer genetics and immuno-oncology. Dr. Kholoud Alwosaibai earned her Ph.D. in Cellular and Molecular Medicine from the University of Ottawa, Canada, focusing on cancer therapeutics, and completed advanced postdoctoral training in immuno-oncology at the same institution. Her educational background also includes a Master’s degree in Medical Biotechnology and a Bachelor’s degree with honors in Biology, complemented by postgraduate certifications from the University of Manchester, Harvard Medical School, and the University of California, San Diego, in bioinformatics, cancer omics, and genomics. Professionally, Dr. Alwosaibai has held various leadership positions, including Head of the Research, Development, and Innovation Unit, Program Manager at the Saudi Genome Satellite Center, and Founder and Vice President of the DAEM Society for Oncology Research. Her research interests span cancer genetics, molecular diagnostics, CAR-T cell therapy, and CRISPR-based genome editing, with a strong focus on precision medicine and the clinical translation of genomic data. Dr. Kholoud Alwosaibai possesses an advanced skill set in next-generation sequencing, cancer variant interpretation, bioinformatics, cellular therapy development, and stem cell research, making her a recognized expert in translational and clinical biomedical research. She has published extensively in high-impact, peer-reviewed journals indexed in Scopus, PubMed, and Web of Science, contributing to global advancements in cancer biology and immunotherapy. Her collaborative work has been featured in leading journals such as Scientific Reports, BMC Cancer, Experimental and Therapeutic Medicine, and Oncotarget. Among her notable recognitions are national research grant awards from the Saudi National Institutes of Health and Sanad Society, as well as an award of excellence from the Saudi Arabian Cultural Bureau in Canada for her outstanding doctoral research performance. Throughout her career, Dr. Kholoud Alwosaibai has demonstrated a strong commitment to mentorship, scientific integrity, and capacity building in Saudi Arabia’s biomedical research landscape. Her visionary leadership, innovative research initiatives, and dedication to developing genomic medicine infrastructure position her as an influential figure in advancing cancer research and personalized therapeutics. In conclusion, Dr. Kholoud Alwosaibai’s professional journey reflects a rare blend of scientific excellence, leadership, and global collaboration, making her an inspiring model for emerging scientists and a driving force for the future of precision oncology and genomic innovation.

Profile: Scopus | ORCID

Featured Publications 

  1. Alwosaibai, K., Abedini, A., Al-Hujaily, E. M., Tang, Y., Garson, K., Collins, O., & Vanderhyden, B. C. (2017). PAX2 maintains the differentiation of oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget. Citations: 85

  2. Gharaibeh, L., Elmadany, N., Alwosaibai, K., & Alshaer, W. (2020). Notch 1 in cancer therapy: Possible clinical implications and challenges. Molecular Pharmacology. Citations: 64

  3. Ghandorah, S., & Alwosaibai, K. (2021). Post-liver transplantation GVHD: Time to consider histocompatibility testing. Journal of Liver Transplantation. Citations: 22

  4. Alwosaibai, K., Al-Hujaily, E. M., Alamri, S., Ghandorah, S., Garson, K., & Vanderhyden, B. C. (2022). PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer. Experimental and Therapeutic Medicine, 23(6), 412. Citations: 37

  5. Alwosaibai, K., Aalmri, S., Mashhour, M., Ghandorah, S., Alshangiti, A., Azam, F., Selwi, W., Gharaibeh, L., Alatawi, Y., Alruwaii, Z., & Alsaab, H. O. (2023). PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers. BMC Cancer, 23(1), 13. Citations: 41

  6. Alessy, S. A., Almotlak, A. A., Alattas, M., Alshareef, A., Alwosaibai, K., Alghamdi, M. A., Razack, H. I. A., & Alqahtani, S. A. (2024). Cancer research challenges and potential solutions in Saudi Arabia: A qualitative discussion group study. JCO Global Oncology, 10, e2300189. Citations: 18

  7. Alwosaibai, K., Alruwaii, Z. I., Mashhour, M., Almsned, F. M., Asraf, R., Alrsheedy, W., Alessa, A., Almohanna, H., Selwi, W., & Azam, F. (2024). Dysgerminomas: Germ cell tumors exhibit high expression of PD-L1 and are associated with high TILs and good prognosis. Scientific Reports, 14(1), 24191. Citations: 12

 

Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award | Pharmaceutical | Abdul Wali Khan University Mardan | Pakistan

Dr. Muhammad Bilal Afridi is a dedicated pharmaceutical scientist and clinical pharmacist recognized for his expertise in drug synthesis, pharmacological modeling, and computational chemistry. With a profound academic background and more than a decade of professional experience, Dr. Afridi has established himself as a leading researcher in the domain of synthetic and therapeutic drug development. He earned his Ph.D. in Pharmaceutical Sciences from Abdul Wali Khan University, Mardan, where his doctoral research focused on the synthesis, characterization, computational studies, and pharmacological potential of synthetic curcumin derivatives aimed at addressing diabetes and amnesia-related disorders. His earlier academic milestones include an M.Phil in Pharmaceutical Sciences from Abdul Wali Khan University and a Doctor of Pharmacy (Pharm-D) from Kohat University of Science and Technology. Professionally, Dr. Muhammad Bilal Afridi has served as a pharmacist at the Institute of Kidney Diseases (IKD), Peshawar, where he managed hospital pharmacy operations, clinical pharmacy services, and patient safety programs. His leadership extended to training junior pharmacists, supervising pharmacy interns, and participating in institutional Drug and Therapeutic Committees. His previous tenures at Rehman Medical Institute and D. Watson Chemist allowed him to develop robust skills in patient counseling, prescription review, pharmacovigilance, and rational drug use. Dr. Afridi’s research interests encompass computational drug design, molecular docking, pharmacodynamics, and synthesis of bioactive compounds, reflecting his interdisciplinary approach that bridges chemistry, pharmacology, and computational biology. His published works in highly regarded journals, including Computational Biology and Chemistry, Inorganic Chemistry Communications, and Current Molecular Pharmacology, contribute significantly to advancing medicinal chemistry and pharmaceutical innovation. He has demonstrated strong analytical and technical skills in density functional theory (DFT) modeling, ADMET prediction, and spectral analysis. Dr. Muhammad Bilal Afridi’s professional competencies include teaching, mentoring, research supervision, and scientific writing, backed by proficiency in tools like EndNote and MS Office. His contributions have been acknowledged through multiple peer-reviewed publications, collaborations with international researchers from Türkiye and Saudi Arabia, and recognition in academic circles for his commitment to scientific excellence. He continues to serve as a role model for young researchers in Pakistan through his dedication to patient-centered research and academic mentorship. His unwavering commitment to bridging pharmaceutical sciences and clinical applications makes him a strong candidate for recognition in global research excellence. Dr. Muhammad Bilal Afridi stands as an emerging leader with a promising future in international pharmaceutical research, committed to innovation, integrity, and impactful contributions to human health and medicine.

Profile: Scopus

Featured Publications 

  1. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). SwissADME studies and density functional theory (DFT) approaches of methyl substituted curcumin derivatives. Computational Biology and Chemistry, 112, 108153. (Cited by 8)

  2. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives. Inorganic Chemistry Communications, 168, 112943. (Cited by 6)

  3. Afridi, M. B., Khan, H., Ali Shah, S. W., Zafar, M., Almalki, A. S., Ghias, M., & Rahman, N. (2022). In-vivo anti-nociceptive activities of Schiff bases aldehyde derivatives of 4-aminoantipyrine and their molecular docking studies. Main Group Chemistry, 21(2), 373–386. (Cited by 10)

  4. Afridi, M. B., Khan, H., Akkol, E. K., & Aschner, M. (2021). Pain perception and management: Where do we stand? Current Molecular Pharmacology, 14(5), 678–688. (Cited by 25)

  5. Afridi, M. B., Sardar, H., Shah, S. W. A., Serdaroğlu, G., & Khan, H. (2025). Exploring anticholinergic and anti-amnesic potential of methyl substituted monocarbonyl curcumin derivatives. European Journal of Pharmacology, 950, 182653. (Cited by 2)

  6. Afridi, M. B., Khan, H., & Shah, S. W. A. (2023). Computational evaluation of synthetic curcumin analogs for neuroprotective potential using molecular docking approaches. Journal of Molecular Structure, 1287, 135623. (Cited by 4)

  7. Afridi, M. B., Sardar, H., & Khan, H. (2023). Pharmacological insights into curcumin derivatives: A computational and experimental perspective. Bioorganic Chemistry, 137, 106707. (Cited by 3)